Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Jan 1;110(4):975–985. doi: 10.1002/cpt.2135

Figure 5.

Figure 5

End-of-treatment quit rates in the PNAT2 trial by treatment and metabolizer group. Odds ratios (OR) with 95% confidence intervals (CI) comparing the efficacy of varenicline versus the nicotine patch. Metabolizer-by-treatment interaction effects --were evaluated by the ratio of odds ratios (ORR) with 95% CI. (A) NMR stratification (slow: NMR<0.31, normal: NMR≥0.31) in the complete varenicline and nicotine patch treatment arms from intent-to-treat dataset (N=838)(22). (B) NMR stratification (slow: NMR<0.31, normal: NMR≥0.31) in the genetically determined AFR and EUR subset of the varenicline and nicotine patch treatment arms (N=679), and (C) AFR wGRS + EUR wGRS stratification (slow: wGRS<2.089 in AFR or 2.140 in EUR, normal: wGRS ≥2.089 in AFR or 2.140 in EUR) in the genetically determined AFR and EUR subset of the varenicline and nicotine patch treatment arms (N=679)